1. Generics Bulletin
  2. >>Business
  3. >>Manufacturing

Portuguese Plant Opens Up Prospects For Hikma To Expand In Europe

 
• By Aidan Fry

Extra capacity coming online at a high-containment facility in Portugal is opening up opportunities for Hikma to expand its presence in Europe’s injectables market.

Cargo_Portugal
Capacity created by opening a high-containment facility in Portugal should help Hikma serve more of Europe's injectables market • Source: Shutterstock

Initiating production at a new high-containment operation facility located near Sintra, Portugal, will give Hikma Pharmaceuticals the opportunity to expand its presence in the European injectable drugs sector, the company’s CEO Siggi Olafsson told Generics Bulletin in an exclusive interview.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Manufacturing

More from Business

Polpharma Looks To Supercharge Biosimilar Development With Help Of Chime

 
• By Dean Rudge

With six biosimilars reportedly in development, Polpharma Biologics has linked up with Chinese CDMO Chime Biologics, looking to tap its “all-in-one solutions to accelerate biosimilar development and reduce the time-to-market” for an undisclosed biosimilar product.

Fresenius Divests Brazilian Sites To EMS Amid Structural Streamlining

 
• By Adam Zamecnik

The divestment marks a further step in Fresenius’ ongoing strategy towards a more optimized and simplified company structure while doubling down on new endeavors in the Biopharma space.

Aurobindo Plots Rivaroxaban Roll-Out As FDA Approves 2.5mg Strength ANDA

 
• By Dean Rudge

Aurobindo is set to join Lupin by competing against Johnson/Bayer’s blockbuster blood thinner Xarelto (rivaroxaban) 2.5mg tablets.